Arvind Gupta
General Partner @ SOSV
San Francisco, United States
Arvind Gupta is a seed investor at SOSV in San Francisco focused on Biotechnology and Health Care. Arvind Gupta co-leads Mayfield’s Engineering Biology practice. He was the first investor in breakout bio companies such as Geltor, Synthex, Prime Roots, NotCo, Prellis, New Culture, DNA Lite and Memphis Meats.As Founder of IndieBio, Arvind redefined the pace and possibilities of early stage biotech, investing in over 136 companies in five years,defining human and planetary health, and growing the IndieBio portfolio into billions of dollars in value. Under his leadership, IndieBio expanded to New York and grew to fifteen investment professionals with a world class adjunct partner board. He is now Venture Advisor at IndieBio.Arvind is the author of Decoding the World: A Roadmap for the Questioner, published by Twelve Books, a division of the Hachette Publishing Group. He was honored with the F50 Global Award for Impact in HealthTech Innovation. He is a frequent speaker at TechCrunch Disrupt, Slush, TedX and Future FoodTech. His work has been profiled in global media outlets such as Bloomberg News, Forbes, The Guardian UK, Neo.life, Nikkei News, Rotman, The Times of India, and CGTN in China. Arvind has been a guest lecturer at UCSF, MIT and Harvard and is a judge at the annual BIO conference startup stadium.Prior to founding IndieBio, Arvind was Design Director at IDEO in Shanghai where he earned numerous international design awards and presented his work at the San Francisco Museum of Modern Art.Arvind received his B.S. in Genetic Engineering from UCSB. He holds 8 patents. Arvind is married to an Icelander and has two daughters.
- Total investments:
- 273
- Last investment:
- Lead investor:
- 31%
Last updated:
For AI agents: llms.txt
Industries Arvind Gupta invests in
Stages Arvind Gupta invests in
Countries Arvind Gupta invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $250k–$8.3M
- Series A
- $5.6M–$18M
Investment Focus
Industry
- Biotechnology 91 (33%)
- Health Care 53 (19%)
- Medical 28 (10%)
- Life Science 20 (7%)
- Food and Beverage 18 (7%)
Stage
- Seed 111 (41%)
- Pre-Seed 43 (16%)
- Convertible Note 35 (13%)
- Series A 20 (7%)
- Series B 9 (3%)
Country
- United States 118 (43%)
- Canada 7 (3%)
- United Kingdom 7 (3%)
- China 2 (1%)
- Chile 1 (0%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Graphon is a company that creates relational representation layers and pre-model intelligence for enterprise AI. | $8.3M / Seed / May 14, 2026 | ||
| Calyx creates versatile sensor platforms that monitor a wide variety of parameters in poultry with high specificity and sensitivity unseen in current technologies. We believe in solving complex challenges in poultry and livestock by integrating AI computer vision technology, bio-engineered sensors, and data science. | Sep 23, 2024 | ||
| Joywell Foods is developing the first healthy, protein sweeteners. Derived from exotic plants, protein sweeteners are rare compounds that provide an amazing taste without the calories. These proteins, produced through fermentation, have no glycemic impact and do not affect the gut microbiome. The company has received regulatory approvals, includingFDA "no questions" letters and GRAS status for multiple proteins | Series C / Aug 01, 2024 | ||
| MycoWorks is engaged in the creation of sustainable design solutions with advanced biomaterials. The company’s proprietary custom-engineered material is sustainable, versatile, and animal-free, and feels and performs like leather. Their first product, Reishi, and the proprietary platform to make it, Fine Mycelium, are a groundbreaking approach tobiomaterials that delivers unparalleled versatility and unmatched performance in strength, durability, and hand feel. The perfect intersection of art and science, Reishi is the only natural material that performs like cowhide leather and is engineered to meet the highest quality standards.MycoWorks was founded by Sophia Wang and Philip Ross in 2013 and is based in Emeryville, California. | Series D / Jul 09, 2024 | ||
| Windfall Bio’s nature-based solution harnesses natural microbes known as mems to capture and transform waste methane from any source into valuable outputs, like fertilizer for organic farming, carbon credits, and progress toward sustainability goals. With Windfall technology, any methane-intensive industry—like oil & gas, agriculture, and wastemanagement—can operate more efficiently while improving profitability and environmental impact. Windfall’s solution makes sense for both small and large operations and high and low concentrations of methane and can be easily and rapidly scaled across the globe, providing a low-cost, low-maintenance way to transform methane emissions into real value. Founded in 2022 and based in San Mateo, CA, Windfall is venture-backed by top-tier firms including Amazon’s Climate Pledge Fund, B37 Ventures, Baruch Future Ventures, Bessemer Venture Partners, Breakthrough Energy Ventures, Cavallo Ventures, Global Brain (through its Norinchukin Innovation Fund L.P.), Incite Ventures, MCJ Collective, Mayfield, Positive Ventures, Prelude Ventures, and UNTITLED (a fund backed by the Tetra Laval family). To learn more about how Windfall is transforming methane from a costly liability into a powerful tool for efficiency and profitability, visit www.windfall.bio. | $28M / Series A / Apr 08, 2024 | ||
| Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics' technology leverages massive gains in print speed and resolution to break the microvasculature barrier.The companywas founded in 2016 and is based in San Francisco, California. | Series C / Nov 17, 2023 | ||
| Biodesigned proteins for beauty, wellness and beyond. | Convertible Note / May 05, 2023 | ||
| Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI andstate-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable. | $15.9M / Series A / May 02, 2023 | ||
| Stämm is a biotechnology company dedicated to making biomanufacturing easy, scalable, sustainable, and repeatable. They are developing accessible, plug-and-play biomanufacturing solutions, allowing an automatized, continuous, and more efficient production of biologics and cell therapies. | Series B / Apr 12, 2023 | ||
| Windfall Bio’s nature-based solution harnesses natural microbes known as mems to capture and transform waste methane from any source into valuable outputs, like fertilizer for organic farming, carbon credits, and progress toward sustainability goals. With Windfall technology, any methane-intensive industry—like oil & gas, agriculture, and wastemanagement—can operate more efficiently while improving profitability and environmental impact. Windfall’s solution makes sense for both small and large operations and high and low concentrations of methane and can be easily and rapidly scaled across the globe, providing a low-cost, low-maintenance way to transform methane emissions into real value. Founded in 2022 and based in San Mateo, CA, Windfall is venture-backed by top-tier firms including Amazon’s Climate Pledge Fund, B37 Ventures, Baruch Future Ventures, Bessemer Venture Partners, Breakthrough Energy Ventures, Cavallo Ventures, Global Brain (through its Norinchukin Innovation Fund L.P.), Incite Ventures, MCJ Collective, Mayfield, Positive Ventures, Prelude Ventures, and UNTITLED (a fund backed by the Tetra Laval family). To learn more about how Windfall is transforming methane from a costly liability into a powerful tool for efficiency and profitability, visit www.windfall.bio. | $9M / Seed / Mar 22, 2023 | ||
| See all 273 investments → | |||
Co-Investors
About SOSV
SOSV is a global venture capital firm that focuses on deep tech investments through the HAX and IndieBio startup development programs aimed at human and planetary health. The firm invests in startups at their inception, providing support to accelerate their next institutional funding round. HAX offers facilities and engineering resources, whileIndieBio provides services and lab equipment for founders. The firm targets deep technology innovations in the health and environmental sectors.
SOSV Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Arvind Gupta
General Partner
|
|||
Blaine Doyle
Mentor
|
|||
Cyril Ebersweiler
General Partner
|
|||
Deborah Zajac
General Partner
|
|||
Duncan Turner
General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Arvind Gupta invest in?
Arvind Gupta invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Pre-Seed stage. Most of the 273 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Arvind Gupta's check size?
Arvind Gupta typically joins rounds of $250k–$8.3M at Seed and $5.6M–$18M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Arvind Gupta participates in.
How do I contact Arvind Gupta?
Public channels for Arvind Gupta include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Arvind Gupta last invest?
The most recent investment recorded for Arvind Gupta closed in May 2026. Shizune tracks 273 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
